Miracor recognized by Red Herring as one of Europe’s 100 most innovating and promising technology companies

“One in three heart attack patients has impaired blood flow even after coronary angioplasty, increasing the risk of death within one year by almost 300 percent. Red Herring recognizes that PICSO^® is designed to help these at-risk patients and, as such, is a significant medical achievement.”

Jon H. Hoem, CEO, Miracor Medical Systems

VIENNA, Austria, April 25, 2012—Miracor Medical Systems GmbH announced today that it has been recognized to receive Red Herring's Top 100 Europe award, a prestigious list honoring the year’s most promising and innovative private technology ventures from the European business region. The winners were selected based upon their technological innovation, management strength, market size, investor record, customer acquisition, and financial health.

On February 28, 2012, Miracor Medical announced that it has received a cash infusion of $3.5 million (€2.6 million) in the form of a research grant from the Austrian Research Promotion Agency (“FFG”), the national funding institution for applied research and development in Austria. The funding will be used primarily to commence the pivotal clinical trial—RAMSES—of the Company’s PICSO^® (Pressure-controlled Intermittent Coronary Sinus Occlusion) system. (Click here for PICSO^® animation.)

About Miracor Medical Systems GmbH
Based in Vienna, Austria, privately held Miracor is commercializing a unique and potentially disruptive technology, PICSO^®, for acute coronary syndrome (ACS), heart failure, and cardiac surgery patients. The Company’s objective is to establish PICSO^® as the standard of care for heart attack patients, thereby improving their quality of life. The initial market opportunity for PICSO^® is 30% of all ACS patients treated per year, which translates into more than 350,000 patients in the U.S. and Europe.

The Miracor PICSO^® Impulse System is CE-marked and can be used during coronary revascularization procedures following myocardial infarction and other types of acute coronary syndromes to intermittently increase the pressure in the coronary venous system. The technology is for investigational use only in the United States at this time.

Download the full press release